Listed

Structure Therapeutics Inc.

GPCRNasdaqCIK 1888886HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$118.6m, Q2 FY2026
Net income−$106.2m, Q2 FY2026
Structure Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m17.5Research and development, Q3 FY2023, three months to 2023-09-30$17.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure20.0Research and development, Q4 FY2023, three months to 2023-12-31$20.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure20.7Research and development, Q1 FY2024, three months to 2024-03-31$20.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure22.1Research and development, Q2 FY2024, three months to 2024-06-30$22.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure32.6Research and development, Q3 FY2024, three months to 2024-09-30$32.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure33.5Research and development, Q4 FY2024, three months to 2024-12-31$33.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure42.9Research and development, Q1 FY2025, three months to 2025-03-31$42.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure54.7Research and development, Q2 FY2025, three months to 2025-06-30$54.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure59.0Research and development, Q3 FY2025, three months to 2025-09-30$59.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure68.7Research and development, Q4 FY2025, three months to 2025-12-31$68.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure66.5Research and development, Q1 FY2026, three months to 2026-03-31$66.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure100Research and development, Q2 FY2026, three months to 2026-06-30$100.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Operating income$m(26.1)Operating income, Q3 FY2023, three months to 2023-09-30−$26.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure(31.0)Operating income, Q4 FY2023, three months to 2023-12-31−$31.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(32.0)Operating income, Q1 FY2024, three months to 2024-03-31−$32.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure(33.3)Operating income, Q2 FY2024, three months to 2024-06-30−$33.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure(45.8)Operating income, Q3 FY2024, three months to 2024-09-30−$45.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure(47.1)Operating income, Q4 FY2024, three months to 2024-12-31−$47.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(56.3)Operating income, Q1 FY2025, three months to 2025-03-31−$56.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(70.5)Operating income, Q2 FY2025, three months to 2025-06-30−$70.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure(73.8)Operating income, Q3 FY2025, three months to 2025-09-30−$73.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure24.0Operating income, Q4 FY2025, three months to 2025-12-31$24.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(89.4)Operating income, Q1 FY2026, three months to 2026-03-31−$89.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(119)Operating income, Q2 FY2026, three months to 2026-06-30−$118.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Income tax$m0.4Income tax, Q3 FY2023, three months to 2023-09-30$405.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure(0.3)Income tax, Q4 FY2023, three months to 2023-12-31−$312.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$29.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure0.1Income tax, Q2 FY2024, three months to 2024-06-30$53.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure0.1Income tax, Q3 FY2024, three months to 2024-09-30$92.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure0.1Income tax, Q4 FY2024, three months to 2024-12-31$136.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2025, three months to 2025-03-31$98.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure0.1Income tax, Q2 FY2025, three months to 2025-06-30$139.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure0.1Income tax, Q3 FY2025, three months to 2025-09-30$108.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure0.2Income tax, Q4 FY2025, three months to 2025-12-31$170.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure0.2Income tax, Q1 FY2026, three months to 2026-03-31$190.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure0.2Income tax, Q2 FY2026, three months to 2026-06-30$234.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Net income$m(23.9)Net income, Q3 FY2023, three months to 2023-09-30−$23.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure(24.5)Net income, Q4 FY2023, three months to 2023-12-31−$24.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(26.0)Net income, Q1 FY2024, three months to 2024-03-31−$26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure(26.0)Net income, Q2 FY2024, three months to 2024-06-30−$26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure(34.0)Net income, Q3 FY2024, three months to 2024-09-30−$34.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure(36.5)Net income, Q4 FY2024, three months to 2024-12-31−$36.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(46.8)Net income, Q1 FY2025, three months to 2025-03-31−$46.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure(61.7)Net income, Q2 FY2025, three months to 2025-06-30−$61.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure(65.7)Net income, Q3 FY2025, three months to 2025-09-30−$65.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure33.0Net income, Q4 FY2025, three months to 2025-12-31$33.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(76.0)Net income, Q1 FY2026, three months to 2026-03-31−$76.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure(106)Net income, Q2 FY2026, three months to 2026-06-30−$106.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Diluted EPS$ per share(0.21)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figurenot reported(0.19)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure(0.18)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure(0.20)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figurenot reported(0.27)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(0.36)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure(0.37)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figurenot reported(0.35)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(0.49)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Basic EPS$ per share(0.21)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figurenot reported(0.19)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure(0.18)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure(0.20)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figurenot reported(0.27)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(0.36)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure(0.37)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figurenot reported(0.35)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(0.49)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure

Balance sheet

Cash and equivalents$272.6m, Q2 FY2026
Shareholders' equity$1.35bn, Q2 FY2026
Structure Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m50.6Cash and equivalents, Q3 FY2023, at 2023-09-30$50.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-17, accession 0001558370-23-019203.Report this figure130Cash and equivalents, FY2023, at 2023-12-31$129.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0001558370-25-001826.Report this figure97.8Cash and equivalents, Q1 FY2024, at 2024-03-31$97.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001558370-24-007642.Report this figure382Cash and equivalents, Q2 FY2024, at 2024-06-30$381.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure172Cash and equivalents, Q3 FY2024, at 2024-09-30$172.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure170Cash and equivalents, FY2024, at 2024-12-31$169.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001104659-26-020562.Report this figure152Cash and equivalents, Q1 FY2025, at 2025-03-31$152.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure147Cash and equivalents, Q2 FY2025, at 2025-06-30$147.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure103Cash and equivalents, Q3 FY2025, at 2025-09-30$102.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure800Cash and equivalents, FY2025, at 2025-12-31$799.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure316Cash and equivalents, Q1 FY2026, at 2026-03-31$316.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure273Cash and equivalents, Q2 FY2026, at 2026-06-30$272.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Current assets$m210Current assets, Q3 FY2023, at 2023-09-30$210.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-17, accession 0001558370-23-019203.Report this figure474Current assets, FY2023, at 2023-12-31$473.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001558370-25-001826.Report this figure449Current assets, Q1 FY2024, at 2024-03-31$449.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001558370-24-007642.Report this figure938Current assets, Q2 FY2024, at 2024-06-30$937.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure924Current assets, Q3 FY2024, at 2024-09-30$923.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure891Current assets, FY2024, at 2024-12-31$891.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001104659-26-020562.Report this figure850Current assets, Q1 FY2025, at 2025-03-31$849.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure799Current assets, Q2 FY2025, at 2025-06-30$799.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure814Current assets, Q3 FY2025, at 2025-09-30$814.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure1,570Current assets, FY2025, at 2025-12-31$1.57bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure1,491Current assets, Q1 FY2026, at 2026-03-31$1.49bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure1,372Current assets, Q2 FY2026, at 2026-06-30$1.37bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Total assets$m216Total assets, Q3 FY2023, at 2023-09-30$216.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-17, accession 0001558370-23-019203.Report this figure482Total assets, FY2023, at 2023-12-31$482.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001558370-25-001826.Report this figure457Total assets, Q1 FY2024, at 2024-03-31$457.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001558370-24-007642.Report this figure947Total assets, Q2 FY2024, at 2024-06-30$947.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure933Total assets, Q3 FY2024, at 2024-09-30$933.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure903Total assets, FY2024, at 2024-12-31$903.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001104659-26-020562.Report this figure867Total assets, Q1 FY2025, at 2025-03-31$866.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure816Total assets, Q2 FY2025, at 2025-06-30$816.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure832Total assets, Q3 FY2025, at 2025-09-30$832.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure1,584Total assets, FY2025, at 2025-12-31$1.58bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure1,508Total assets, Q1 FY2026, at 2026-03-31$1.51bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure1,425Total assets, Q2 FY2026, at 2026-06-30$1.43bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Current liabilities$m20.1Current liabilities, Q3 FY2023, at 2023-09-30$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-17, accession 0001558370-23-019203.Report this figure24.7Current liabilities, FY2023, at 2023-12-31$24.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001558370-25-001826.Report this figure23.6Current liabilities, Q1 FY2024, at 2024-03-31$23.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001558370-24-007642.Report this figure22.7Current liabilities, Q2 FY2024, at 2024-06-30$22.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure33.4Current liabilities, Q3 FY2024, at 2024-09-30$33.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure36.0Current liabilities, FY2024, at 2024-12-31$36.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001104659-26-020562.Report this figure36.5Current liabilities, Q1 FY2025, at 2025-03-31$36.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure39.0Current liabilities, Q2 FY2025, at 2025-06-30$39.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure57.5Current liabilities, Q3 FY2025, at 2025-09-30$57.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure63.3Current liabilities, FY2025, at 2025-12-31$63.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure57.0Current liabilities, Q1 FY2026, at 2026-03-31$57.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure66.1Current liabilities, Q2 FY2026, at 2026-06-30$66.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Total liabilities$m23.4Total liabilities, Q3 FY2023, at 2023-09-30$23.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-17, accession 0001558370-23-019203.Report this figure29.1Total liabilities, FY2023, at 2023-12-31$29.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001558370-25-001826.Report this figure27.4Total liabilities, Q1 FY2024, at 2024-03-31$27.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001558370-24-007642.Report this figure26.0Total liabilities, Q2 FY2024, at 2024-06-30$26.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure36.4Total liabilities, Q3 FY2024, at 2024-09-30$36.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure38.5Total liabilities, FY2024, at 2024-12-31$38.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001104659-26-020562.Report this figure41.9Total liabilities, Q1 FY2025, at 2025-03-31$41.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure44.4Total liabilities, Q2 FY2025, at 2025-06-30$44.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0001558370-25-010541.Report this figure62.1Total liabilities, Q3 FY2025, at 2025-09-30$62.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure67.5Total liabilities, FY2025, at 2025-12-31$67.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure61.0Total liabilities, Q1 FY2026, at 2026-03-31$61.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure71.0Total liabilities, Q2 FY2026, at 2026-06-30$71.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure
Shareholders' equity$m193Shareholders' equity, Q3 FY2023, at 2023-09-30$193.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure453Shareholders' equity, FY2023, at 2023-12-31$453.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001104659-26-020562.Report this figure430Shareholders' equity, Q1 FY2024, at 2024-03-31$429.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure921Shareholders' equity, Q2 FY2024, at 2024-06-30$921.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure897Shareholders' equity, Q3 FY2024, at 2024-09-30$896.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure865Shareholders' equity, FY2024, at 2024-12-31$864.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure825Shareholders' equity, Q1 FY2025, at 2025-03-31$824.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure772Shareholders' equity, Q2 FY2025, at 2025-06-30$772.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure770Shareholders' equity, Q3 FY2025, at 2025-09-30$770.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure1,516Shareholders' equity, FY2025, at 2025-12-31$1.52bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure1,447Shareholders' equity, Q1 FY2026, at 2026-03-31$1.45bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure1,354Shareholders' equity, Q2 FY2026, at 2026-06-30$1.35bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure

Cash flow

Operating cash flow−$120.1m, Q2 FY2026
Capital expenditure−$42.0k, Q2 FY2026
Structure Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(20.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$20.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015531. Derived: 9-month figure less the 6-month figure.Report this figure(21.7)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$21.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(34.1)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$34.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure(26.4)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$26.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0001558370-25-010541. Derived: 6-month figure less the 3-month figure.Report this figure(19.7)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$19.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107829. Derived: 9-month figure less the 6-month figure.Report this figure(36.5)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$36.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure(52.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$52.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(54.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$54.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092057. Derived: 6-month figure less the 3-month figure.Report this figure(51.0)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$51.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107829. Derived: 9-month figure less the 6-month figure.Report this figure(64.4)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$64.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure15.2Operating cash flow, Q1 FY2026, three months to 2026-03-31$15.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(120)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$120.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092057. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.8Capital expenditure, Q3 FY2023, three months to 2023-09-30$820.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015531. Derived: 9-month figure less the 6-month figure.Report this figure1.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$162.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure0.4Capital expenditure, Q2 FY2024, three months to 2024-06-30$427.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-06, accession 0001558370-25-010541. Derived: 6-month figure less the 3-month figure.Report this figure0.7Capital expenditure, Q3 FY2024, three months to 2024-09-30$685.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107829. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2025, three months to 2025-03-31$314.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$232.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092057. Derived: 6-month figure less the 3-month figure.Report this figure1.6Capital expenditure, Q3 FY2025, three months to 2025-09-30$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107829. Derived: 9-month figure less the 6-month figure.Report this figure1.5Capital expenditure, Q4 FY2025, three months to 2025-12-31$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020562. Derived: 12-month figure less the 9-month figure.Report this figure1.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure(0.0)Capital expenditure, Q2 FY2026, three months to 2026-06-30−$42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092057. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)217.96m, Q2 FY2026
Structure Therapeutics Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares9.8Diluted shares (weighted), period not labelled, three months to 2022-09-309,780,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-17, accession 0001558370-23-019203.Report this figure71.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3171,655,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001558370-24-007642.Report this figure115Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30114,759,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure115Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30114,948,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015531.Report this figure140Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31139,710,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001558370-25-006989.Report this figure148Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30148,239,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001558370-24-011616.Report this figure172Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30171,630,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure172Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31172,051,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure173Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30172,647,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure175Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30175,469,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107829.Report this figure217Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31217,326,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057230.Report this figure218Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30217,957,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure

Shares outstanding: 213.93mShares outstanding, period not labelled, at 2026-07-31213,929,572 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-092057.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.